These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 30808293)

  • 1. Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials.
    Scheeren TWL; Welte T; Saulay M; Engelhardt M; Santerre-Henriksen A; Hamed K
    BMC Infect Dis; 2019 Feb; 19(1):195. PubMed ID: 30808293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia.
    Awad SS; Rodriguez AH; Chuang YC; Marjanek Z; Pareigis AJ; Reis G; Scheeren TW; Sánchez AS; Zhou X; Saulay M; Engelhardt M
    Clin Infect Dis; 2014 Jul; 59(1):51-61. PubMed ID: 24723282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.
    Syed YY
    Drugs; 2014 Sep; 74(13):1523-42. PubMed ID: 25117196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftobiprole for the treatment of pneumonia: a European perspective.
    Liapikou A; Cillóniz C; Torres A
    Drug Des Devel Ther; 2015; 9():4565-72. PubMed ID: 26316697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of ceftobiprole in patients aged 65 years or older: a 
    Welte T; Scheeren TW; Overcash JS; Saulay M; Engelhardt M; Hamed K
    Future Microbiol; 2021 May; 16():543-555. PubMed ID: 33960817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation.
    Nicholson SC; Welte T; File TM; Strauss RS; Michiels B; Kaul P; Balis D; Arbit D; Amsler K; Noel GJ
    Int J Antimicrob Agents; 2012 Mar; 39(3):240-6. PubMed ID: 22230331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 3, Randomized, Investigator-blinded Trial Comparing Ceftobiprole With a Standard-of-care Cephalosporin, With or Without Vancomycin, for the Treatment of Pneumonia in Pediatric Patients.
    Bosheva M; Gujabidze R; Károly É; Nemeth A; Saulay M; Smart JI; Hamed KA
    Pediatr Infect Dis J; 2021 Jun; 40(6):e222-e229. PubMed ID: 33480665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A
    Huang H; Gao L; Engelhardt M; Saulay M; Hamed K
    Future Microbiol; 2021 Jul; 16():783-796. PubMed ID: 34155899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations.
    Torres A; Mouton JW; Pea F
    Clin Pharmacokinet; 2016 Dec; 55(12):1507-1520. PubMed ID: 27272266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftobiprole and pneumonia in adults admitted to the emergency department is it time to assess a new therapeutic algorithm?
    Crapis M; Venturini S; Della Siega P; Tonizzo M; Garlatti E; Rosa R; Basso B; Pontoni E
    J Chemother; 2021 May; 33(3):174-179. PubMed ID: 32996844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftobiprole medocaril in the treatment of hospital-acquired pneumonia.
    Scheeren TW
    Future Microbiol; 2015; 10(12):1913-28. PubMed ID: 26573022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftobiprole for the treatment of pneumonia.
    Cillóniz C; Dominedò C; Garcia-Vidal C; Torres A
    Rev Esp Quimioter; 2019 Sep; 32 Suppl 3(Suppl 3):17-23. PubMed ID: 31364337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftobiprole: drug evaluation and place in therapy.
    Giacobbe DR; De Rosa FG; Del Bono V; Grossi PA; Pea F; Petrosillo N; Rossolini GM; Tascini C; Tumbarello M; Viale P; Bassetti M
    Expert Rev Anti Infect Ther; 2019 Sep; 17(9):689-698. PubMed ID: 31553250
    [No Abstract]   [Full Text] [Related]  

  • 14. Hospital-acquired pneumonia and ventilator-associated pneumonia in adults at Siriraj Hospital: etiology, clinical outcomes, and impact of antimicrobial resistance.
    Werarak P; Kiratisin P; Thamlikitkul V
    J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S126-38. PubMed ID: 20364567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial.
    Zhong NS; Sun T; Zhuo C; D'Souza G; Lee SH; Lan NH; Chiang CH; Wilson D; Sun F; Iaconis J; Melnick D
    Lancet Infect Dis; 2015 Feb; 15(2):161-71. PubMed ID: 25539586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftobiprole medocaril for the treatment of community-acquired pneumonia.
    Falcó V; Burgos J; Almirante B
    Expert Opin Pharmacother; 2018 Sep; 19(13):1503-1509. PubMed ID: 30198789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of ceftriaxone plus macrolide and ampicillin/sulbactam plus macrolide in treatment for patients with community-acquired pneumonia without risk factors for aspiration: an open-label, quasi-randomized, controlled trial.
    Hamao N; Ito I; Konishi S; Tanabe N; Shirata M; Oi I; Tsukino M; Matsumoto H; Yasutomo Y; Kadowaki S; Hirai T
    BMC Pulm Med; 2020 Jun; 20(1):160. PubMed ID: 32503515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia.
    Lagacé-Wiens PR; Rubinstein E
    Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):789-99. PubMed ID: 23590397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of cefepime versus ceftazidime in the treatment of adult pneumonia.
    Lin JC; Yeh KM; Peng MY; Chang FY
    J Microbiol Immunol Infect; 2001 Jun; 34(2):131-7. PubMed ID: 11456359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point.
    File TM; Eckburg PB; Talbot GH; Llorens L; Friedland HD
    Int J Antimicrob Agents; 2017 Aug; 50(2):247-251. PubMed ID: 28599867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.